Safety and efficacy of tirofiban combined with endovascular treatment in acute ischaemic stroke

• DOI: 10.1111/ene.13946
• Publication Date: 2019-02-22T04:15:44Z
• Authors: X. Pan; D. Zheng; Y. Zheng; P. W. L. Chan; Y. Lin; J. Zou; J. Zhou; J. Yang
• Keywords: Tirofiban; Stroke

Background and purpose Tirofiban is used off‐label in clinical practice for acute ischaemic stroke ( AIS ). However, it unknown whether tirofiban increases the bleeding risk or improves outcome of endovascular treatment EVT ) . This study evaluated efficacy safety combination with Methods Consecutive patients receiving were included prospective registry from 2015 to 2018. The outcomes modified Rankin Scale mRS score at 3 months National Institutes Health Stroke NIHSS 24 h. symptomatic intracerebral hemorrhage sICH ), any in‐hospital hemorrhage, death 3‐month death. Results Of 211 patients, 82 (38.9%) received tirofiban. A total 39 (48.1%) 44 (36.1%) without had 0–2 [adjusted odds ratio OR 2.41; 95% confidence interval CI 1.11–5.23, P = 0.026]. h was lower group (9.5 vs. 12.0, adjusted 0.032). Five (6.1%) 16 (12.4%) (adjusted , 0.54; 0.16–1.83, 0.32). In‐hospital occurred 10 (12.2%) 41 (31.8%) 0.32; 0.13–0.76, 0.01). 7 (8.5%) 0.69; 0.22–2.13, 0.52). 13 (15.9%) 22 (17.1%) dead 0.98; 0.40–2.40, 0.96). Conclusions associated a It not higher rate months.